Trial reportJournal of the American Society of Hypertension : JASH
Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients.
Trial report in Journal of the American Society of Hypertension : JASH. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Chronotherapy for Hypertension: A Meta-Analysis and Systematic Review of RCTs.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Pooled it
- Evening versus morning dosing regimen drug therapy for hypertension.The Cochrane database of systematic reviews · 2024Pooled it
- Chronotherapy for morning blood pressure surge in hypertensive patients: a systematic review and meta-analysis.BMC cardiovascular disorders · 2021Pooled it
- Circadian Variation in Efficacy of Medications.Clinical pharmacology and therapeutics · 2021Review
- CLOCK-BMAL1 regulates circadian oscillation of ventricular arrhythmias in failing hearts through β1 adrenergic receptor.American journal of translational research · 2020Article
- The Molecular Genetic Interaction Between Circadian Rhythms and Susceptibility to Seizures and Epilepsy.Frontiers in neurology · 2020Review
- Blood Pressure Variability and Therapeutic Implications in Hypertension and Cardiovascular Diseases.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2019Review
- Autonomic nerves and circadian control of renal function.Autonomic neuroscience : basic & clinical · 2019Review
- Circadian regulation of kidney function: finding a role for Bmal1.American journal of physiology. Renal physiology · 2018Review
- Morning blood pressure surge: pathophysiology, clinical relevance and therapeutic aspects.Integrated blood pressure control · 2018Review
- Therapeutic applications of circadian rhythms for the cardiovascular system.Frontiers in pharmacology · 2015Review
- Theory of Inpatient Circadian Care (TICC): A Proposal for a Middle-Range Theory.The open nursing journal · 2015Article
- The current status of beta blockers' use in the management of hypertension.Saudi medical journal · 2014Review
- Participation of hypertension patients in early-phase clinical trials.Journal of clinical hypertension (Greenwich, Conn.) · 2014Article
- Hypertension: is it time to replace drugs with nutrition and nutraceuticals?P & T : a peer-reviewed journal for formulary management · 2014Article
- Chronopharmacology of anti-convulsive therapy.Current neurology and neuroscience reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The morning blood pressure surge (MBPS) has been shown to be an independent predictor of cardiovascular events. There is insufficient evidence on the effect of nebivolol, a vasodilating β1-receptor blocker, on the MBPS when given in the morning or the evening. This is a prospective, randomized, double-blind, crossover study designed to test morning vs. evening dosing of nebivolol in nondiabetic, hypertensive patients. Patients received nebivolol 5 mg/day (force-titrated to 10 mg/day after 1 week) in the morning or evening and corresponding placebos. Patients underwent ambulatory BP monitoring at baseline and after each treatment phase. Forty-two patients were randomized, of whom 38 completed both study periods. Both morning and evening dosed nebivolol significantly lowered daytime, nighttime, and 24-hour BP after 3 weeks of treatment. Evening (but not morning) dosing significantly reduced prewaking systolic BP from baseline (8.64 ± 26.46 mm Hg, P = .048). Nebivolol given in the morning or the evening significantly reduces 24-hour BP parameters. Evening dosed nebivolol may confer some advantage over morning dosing in reducing prewaking systolic BP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.